“We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia,” says Shai N. Gozani, MD, PhD, president and CEO of NeuroMetrix, in a media release from the Waltham, Mass-headquartered company.
“This clinical evaluation will provide additional evidence for fibromyalgia patients and their healthcare providers who are considering Quell as a pain relief option,” Gozani adds.
“Clinical research on innovative therapies is an integral part of what we do,” states Kunal Gogna, MD, from Synovation Medical Group. “We are excited to test the Quell technology and potentially add it to our multidisciplinary approach to pain management.”
Quell is an FDA-approved wearable device for treatment of chronic pain without a prescription.
[Source(s): NeuroMetrix Inc, Business Wire]